Roche Upbeat On Recent Launches, Oncology And Actemra To Drive Growth Through Mid-Term
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche presented a mixed sales picture across regions and products in a first quarter 2012 earnings call. Management highlighted a busy regulatory quarter with two new NME launches and five positive Phase III trials and filings, but also reported generic and competitive threats to key products.
You may also be interested in...
Chugai Launches New Mid-term Plan With Investment Prospects; Eisai Battles For Its Growth Drivers – Japan Earnings Profiles
Japan’s earnings season highlights new global strategies for Japan’s leading pharmaceutical companies.
ASCO Data Support Roche’s Grand Plan For Non-Stop Avastin Treatment
After the loss of the breast cancer indication for Avastin, Roche looks to long-term treatment in colon cancer as growth driver. And fourth Phase III study of Avastin in ovarian cancer proves positive as the drug makes commercial headway in European markets where it is approved for this indication.
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.